Today: 29 April 2026
Browse Category

NYSE:MO 30 October 2025 - 25 April 2026

Altria Stock Faces a Crucial Earnings Test as Marlboro Maker’s Smoke-Free Bet Nears Judgment Day

Altria Stock Faces a Crucial Earnings Test as Marlboro Maker’s Smoke-Free Bet Nears Judgment Day

Altria shares closed at $66.88 Friday, valuing the company at about $114.9 billion ahead of first-quarter results due April 30. CEO Billy Gifford retires May 14, with CFO Sal Mancuso set to succeed him. Analysts expect Q1 earnings of $1.25 a share on $4.58 billion revenue. Altria’s smokeable-products revenue fell 1.6% in 2025 as U.S. cigarette volumes declined.
25 April 2026
·
Altria stock price rebounds as MO investors size up 2026 outlook, export tax break and CEO change

Altria stock price rebounds as MO investors size up 2026 outlook, export tax break and CEO change

Altria shares rose 3.1% to $61.61 Friday, rebounding after Thursday’s earnings report sent the stock lower. The company named CFO Salvatore Mancuso as incoming CEO, effective May 14, and is expanding exports to tap a federal excise-tax rebate. Altria’s Q4 net revenue fell 2.1% to $5.846 billion, with adjusted EPS at $1.30. Market share for its on! pouches dropped to 13% as competition from Philip Morris’s Zyn intensified.
30 January 2026
·
Altria Stock (MO) News: Dividend Reset, FDA on! PLUS Authorization, and NJOY Legal Battle—What Investors Need Before Monday

Altria Stock (MO) News: Dividend Reset, FDA on! PLUS Authorization, and NJOY Legal Battle—What Investors Need Before Monday

Altria shares closed at $57.60 Friday, down 2.33% after the stock went ex-dividend for a $1.06 payout payable Jan. 9. After-hours trading showed little change, with MO near $57.64. The drop followed the ex-dividend adjustment and came as Altria notched a regulatory win for on! PLUS nicotine pouches and faced ongoing NJOY-Juul legal disputes.
28 December 2025
··
Altria Group Stock (MO) Slides After Ex-Dividend Session as Investors Track NJOY Legal Fight and FDA Green Light for on! PLUS Nicotine Pouches

Altria Group Stock (MO) Slides After Ex-Dividend Session as Investors Track NJOY Legal Fight and FDA Green Light for on! PLUS Nicotine Pouches

Altria shares fell 2.34% to $57.60 Friday as the stock traded ex-dividend, with the $1.06 per share payout set for Jan. 9. Juul Labs asked an Arizona judge to block Altria and NJOY from using documents uploaded to a UCSF database, arguing the records could affect a vape patent dispute. The broader market saw light trading and finished slightly lower.
27 December 2025
··
Altria (MO) Stock in Focus: FDA Clears on! PLUS Nicotine Pouches, Dividend Dates, and the Latest Analyst Forecasts Into 2026

Altria (MO) Stock in Focus: FDA Clears on! PLUS Nicotine Pouches, Dividend Dates, and the Latest Analyst Forecasts Into 2026

The FDA late Friday authorized marketing of six on! PLUS nicotine pouch products, the first such decision under a new pilot review program. Altria shares closed at $58.07, market cap $97.48 billion, ahead of a key dividend ex-date and after the company confirmed plans to resume retail and online sales for the approved pouches. The authorization covers three flavors in two strengths, with strict packaging and marketing restrictions.
21 December 2025
··
Altria (MO) Stock News Today: Big Institutional Moves, 7%+ Dividend Yield and a Valuation Debate – November 29, 2025

Altria (MO) Stock News Today: Big Institutional Moves, 7%+ Dividend Yield and a Valuation Debate – November 29, 2025

Altria shares closed at $59.01 on November 28, 2025, with a forward dividend yield near 7.2% and a market cap just under $99 billion. Groupama Asset Management increased its stake by 18.9% in Q2, while other institutional filings showed mixed activity. Debate continued over whether Altria is undervalued or a value trap, following a widely circulated analysis.
30 November 2025
·
Altria Stock Slips After Mixed Q3 Earnings – Big Buyback and 8% Dividend Tempt Investors

Altria Stock Slips After Mixed Q3 Earnings – Big Buyback and 8% Dividend Tempt Investors

Altria reported Q3 net revenue down 3% to $6.07 billion and adjusted EPS of $1.45, matching estimates. Shares fell nearly 4% pre-market, trading about 10% below recent highs. The company doubled its buyback program to $2 billion and raised its 2025 earnings outlook floor. Cigarette and oral tobacco sales declined, while NJOY e-cigarette sales remain halted due to a patent dispute.
30 October 2025
···

Stock Market Today

  • Nasdaq Futures Rise Ahead of Fed Decision and Major Tech Earnings
    April 29, 2026, 9:10 AM EDT. Nasdaq futures gained 0.4% ahead of the Federal Reserve's policy decision and earnings reports from tech giants Alphabet, Microsoft, Amazon, and Meta. Markets are cautious following a broad sell-off in major indices driven by chip stock weakness linked to slowing growth at AI firm OpenAI. Investors await the Fed's stance on inflation and interest rates, with crude oil prices rising amid unresolved US-Iran tensions. The Fed is expected to hold rates steady in Jerome Powell's final meeting before his replacement, Kevin Warsh, awaits Senate approval. Key focus remains on AI capital expenditure and the potential for further rate hikes in 2024. Earnings from AbbVie, AstraZeneca, Total Energies, UBS, and GSK are also in focus.

Latest article

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Humana Stock Drops After Earnings Beat: Medicare Advantage Headwind Keeps Pressure On

Humana Stock Drops After Earnings Beat: Medicare Advantage Headwind Keeps Pressure On

29 April 2026
Humana beat first-quarter profit estimates, earning $10.31 per share adjusted, but shares fell over 6% premarket after it kept its 2026 profit outlook unchanged and cut its GAAP earnings forecast. Revenue rose to $39.65 billion. The insurer cited lower Medicare Star Ratings for the earnings decline and said medical and pharmacy costs are “slightly better” than expected. Competitors Centene, UnitedHealth, and Elevance recently raised their annual forecasts.
Go toTop